TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Simcere Pharmaceutical Group Limited ( (HK:2096) ) has shared an update.
Simcere Pharmaceutical Group Limited announced that its new drug application for Rademikibart, developed in collaboration with Connect Biopharma, was accepted by China’s National Medical Products Administration. Rademikibart is a monoclonal antibody targeting IL-4R, designed to treat Th2-related inflammatory diseases like atopic dermatitis and asthma. This development enhances Simcere’s position in the pharmaceutical industry, potentially offering new treatment options for patients with significant unmet medical needs.
More about Simcere Pharmaceutical Group Limited
Simcere Pharmaceutical Group Limited is an innovation and R&D-driven pharmaceutical company focusing on neuroscience, anti-oncology, autoimmune, and anti-infection therapeutic areas. The company has established a ‘State Key Laboratory of Neurology and Oncology Drug Development’ and aims to address significant clinical needs through strategic partnerships and in-house research.
Average Trading Volume: 17,335,305
Technical Sentiment Signal: Buy
Current Market Cap: HK$27.27B
Learn more about 2096 stock on TipRanks’ Stock Analysis page.